Breast Cancer Drug Tamoxifen May be Enhanced by Lipid Carriers With Melatonin

Breast Cancer Drug Tamoxifen May be Enhanced by Lipid Carriers With Melatonin
Nanosized fat bubbles packed with the hormone melatonin might make the breast cancer drug tamoxifen more effective and reduce side effects in the process. The nanostructured lipid carriers also may lower the risk of developing chemoresistance, when the body is lax to respond or does  not respond at all to therapies. Tamoxifen is the most frequently used drug to treat breast cancer, but as with many other cancer treatments, it is linked to severe health-related issues, such as uterine or other types of cancer, stroke, lung embolisms and vision problems. Less severe, but more frequent side effects include weight loss, irregular menstruation and hot flashes. Melatonin is a natural, hormonal sleeping aid that fluctuates with normal sleep and wake cycles. Earlier studies have indicated that the hormone can help kill cancer cells when used with some chemotherapuetic drugs, but its effects with tamoxifen were not well explored. "We tried to solve both issues by putting melatonin into nanostructures so they can help the chemotherapeutic agent kill more cells," said Nasser Samadi, head of the Department of Biochemistry and Genetics at Tabriz University of Medical Sciences in Iran, in a press release. "By doing this, you can decrease the dose of tamoxifen needed, reducing the severity of the side effects." Samadi was the first author of the study  “Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment,  published in the journal 
Subscribe or to access all post and page content.